Medtronic plc cash flow to debt ratio of 26.22% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Medtronic plc's free cash flow has increased 4.65% from $5.18B last year to $5.43B, signaling increasing performance

Medtronic plc's debt to equity ratio is 0.57, which means that the company's assets are healthy financed, signaling financial stability.

Medtronic plc's debt has decreased relative to shareholder equity from 0.59 last year to 0.57 today, signaling strengthened financials

Medtronic plc has a net debt to EBITDA ratio of 1.91x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Medtronic plc's interest coverage ratio of 9.04 indicates that earnings with good margin can cover interest payments on company debt

Medtronic plc's profit margin has decreased (5.04%) in the last year from 13.90% to 13.20%, signaling decreasing performance

Medtronic plc's short-term assets of $24.79B exceed its short-term liabilities of $11.66B

Medtronic plc's return on assets of 5.16% is higher than the 5.00% threshold, indicating efficient asset utilization

Medtronic plc's return on equity of 9.85%, is lower than 15.00%, indicating bad performance

Medtronic plc's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Medtronic plc had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Medtronic plc has positive free cash flow, indicating the company generates cash after capital expenditures

Medtronic plc has a free cash flow yield of 4.74%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Medtronic plc's yearly earnings has increased 2.96% since last year from $4.66B to $4.80B, signaling increasing performance

Medtronic plc's yearly revenue has increased 8.43% since last year from $33.54B to $36.36B, signaling increasing performance

ROIC 6.13% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Medtronic plc's 3-year revenue CAGR of 5.21% is positive, indicating growing revenue over the past 3 years

Medtronic plc had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Medtronic plc had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Medtronic plc is overvalued relative to its fair value price of 21.14 based on Discounted Cash Flow model

Medtronic plc has an earnings yield of 4.19%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Medtronic plc is overvalued relative to its fair value price of 29.78 based on EBITDA multiple model

Medtronic plc has an EV/EBITDA ratio of 13.58x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Medtronic plc is overvalued relative to its fair value price of 64.83 based on Earnings Fair Value model

Medtronic plc has a PEG-ratio over 1 which is considered overvalued

Medtronic plc has a price-to-book ratio of 2.29x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Medtronic plc has a price-to-sales ratio of 3.15x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue